EGFR and cancer: In cancer context, ANXA1 regulates macrophages activation by inhibiting the expression and activation of the inducible nitric oxide synthase (iNOS) (Smyth et al., 2006) or regulating nuclear EGFR and EGFR/STAT3 signaling pathway to ultimately create an immunosuppressive environment that facilitates cancer progression (Araújo et al., 2021).